Bicara Therapeutics BCAX Cash Flow Statement
| FY'25 | FY'24 | ||
|---|---|---|---|
| -$137.95M-103% | -$68M-30.8% | ||
| $105K+87.5% | $56K— | ||
| $15.01M+103% | $7.4M— | ||
| -$5.58M-133% | $16.91M— | ||
| —— | —— | ||
| -$932K-1,251% | $81K— | ||
| -$106.83M-42.9% | -$74.75M— | ||
| $280K+294% | $71K— | ||
| —— | —— | ||
| -$318.45M— | —— | ||
| $29.5M-91.2% | $333.48M— | ||
| $32.26M-90.4% | $335.01M— | ||
| -$393.03M-211% | $355.14M— | ||
| —— | —— | ||
| —— | —— | ||
| $105K+87.5% | $56K— | ||
| -$932K-1,251% | $81K— | ||
| -$5.58M-133% | $16.91M— | ||
| —— | —— | ||
| $895K+1,262% | -$77K-186% | ||
| —— | —— | ||
| —— | —— | ||
| -$107.11M-43.2% | -$74.82M— | ||
| -$107.11M-43.2% | -$74.82M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Bicara Therapeutics's cash flow data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.